Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 8, Issue 368, Pages 368ra171-368ra171
Publisher
American Association for the Advancement of Science (AAAS)
Online
2016-12-08
DOI
10.1126/scitranslmed.aag1298
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides
- (2015) Jason Brayer et al. AMERICAN JOURNAL OF HEMATOLOGY
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)
- (2015) C. Kahl et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia
- (2014) Marion Subklewe et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia
- (2013) Richard Champlin BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
- (2013) D. Stroopinsky et al. CANCER RESEARCH
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
- (2013) J. Rosenblatt et al. CLINICAL CANCER RESEARCH
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
- (2010) J. Rosenblatt et al. BLOOD
- Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
- (2010) V. F. Van Tendeloo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
- (2009) U. Keilholz et al. BLOOD
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started